Welcome to our dedicated page for Accendra Health SEC filings (Ticker: ACH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Accendra Health, Inc. (NYSE: ACH) SEC filings page on Stock Titan is intended to provide access to the company’s regulatory disclosures once they are available from the SEC’s EDGAR system. While no specific filings are listed in the provided data, this page is designed to surface documents that explain how Accendra Health describes its business, risks and financial condition in formal reports.
Accendra Health states that it is a nationwide provider of products, technology and services that support health beyond the hospital, focusing on chronic and complex health conditions. When available, annual reports on Form 10-K and quarterly reports on Form 10-Q can offer detailed discussion of these activities, including segment descriptions, risk factors and management’s analysis of operations related to areas such as diabetes, sleep health, wound care, respiratory care, urology and ostomy.
Stock Titan enhances these filings with AI-powered summaries that highlight key themes, helping readers understand long, technical documents more efficiently. As Accendra Health’s filings appear, users will be able to review:
• Annual reports (Form 10-K) with AI-generated overviews of the company’s business description and risk disclosures.
• Quarterly reports (Form 10-Q) summarizing operational updates and changes in the business.
• Current reports (Form 8-K) that may cover significant events, such as corporate transactions or changes in strategy.
• Insider transaction reports (Form 4), once filed, to track reported purchases and sales by directors and officers.
Filings are updated in real time as they are released by the SEC, and AI summaries aim to clarify complex sections without altering the underlying content. This allows investors and researchers to quickly identify the portions of Accendra Health’s disclosures that relate to its focus on health beyond the hospital and support for chronic and complex conditions.
Accendra Health, Inc. is asking shareholders to vote at its virtual 2026 Annual Meeting on six director nominees, auditor ratification, a say-on-pay advisory vote, and approval of an amended 2023 Omnibus Incentive Plan. The record date is March 18, 2026, and the meeting will be held online on May 14, 2026.
The company highlights its strategic shift after selling its Products & Healthcare Services business on December 31, 2025, becoming a more focused, pure-play home-based care provider through its Apria and Byram Healthcare brands. For 2025, Accendra generated total revenue of $10.672 billion, total adjusted operating income of $215 million, adjusted EBITDA of $424 million, and total adjusted net income per share of $0.61, using non-GAAP measures reconciled in Appendix B.
Proxy materials emphasize corporate governance practices such as a majority voting standard for uncontested director elections, proxy access, independent board leadership, and board-level oversight of risk, ESG, and cybersecurity. Executive pay is heavily performance-based, with the CEO’s 2025 target compensation 90% variable, including annual incentives tied to adjusted EBITDA, revenue, and net debt reduction, and long-term incentives split between performance share units and restricted stock units.
Accendra Health, Inc. Schedule 13G: Kevin M. Webb reports beneficial ownership of 4,287,431 shares of Common Stock, representing 5.61% of the class as of 03/12/2026. The filing states Mr. Webb has sole voting power and sole dispositive power over all 4,287,431 shares.
The submission lists the issuer address as 10900 Nuckols Road, Suite 400, Glen Allen, Virginia, and is signed by Kevin M. Webb on 03/30/2026.
Accendra Health Inc amendment to a Schedule 13G/A states that The Vanguard Group reports 0 shares beneficially owned of Accendra Health Inc common stock as of the filing. The amendment notes an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries report beneficial ownership separately. The filing is signed by Ashley Grim, Head of Global Fund Administration, on 03/26/2026.
Accendra Health President & CEO Edward A. Pesicka reported a tax-related share disposition, not an open-market stock sale. On the Form 4, 58,945 shares of common stock were surrendered at $2.03 per share to cover tax withholding tied to vesting of restricted stock.
These shares were delivered back to the company rather than sold to outside investors. After this transaction, Pesicka directly holds 1,090,477 shares of Accendra Health common stock, indicating he retains a substantial equity position in the company.
ACCENDRA HEALTH INC/VA/ executive reports routine tax withholding share disposition. EVP & CFO Jonathan A. Leon surrendered 11,286 shares of common stock on 2026-03-20 to the company to cover tax withholding tied to vesting of restricted stock. This was not an open-market sale. After the transaction, he directly holds 292,303 shares of common stock.
Accendra Health executive Perry A. Bernocchi reported a routine tax-related share disposition. On March 20, 2026, he surrendered 20,841 shares of common stock at $2.03 per share to the company to satisfy tax withholding obligations tied to vesting restricted stock. This was not an open-market sale, and he still directly holds 321,821 shares after the transaction.
Accendra Health executive Heath H. Galloway transferred 9,347 shares of common stock to the company at $2.03 per share to cover tax withholding on vested restricted stock. This non‑market, tax-withholding disposition leaves him holding 169,094 shares directly, reflecting a routine compensation-related adjustment rather than an open-market trade.
Bernocchi Perry A reported acquisition or exercise transactions in this Form 4 filing.
Accendra Health executive Perry A. Bernocchi, EVP and Chief Operating Officer, received a grant of 108,696 shares of Common Stock as equity compensation. The restricted stock grant vests one-third per year over three years. Following this award, his directly held stake totals 342,662 shares.
Leon Jonathan A reported acquisition or exercise transactions in this Form 4 filing.
ACCENDRA HEALTH INC/VA/ EVP & CFO Jonathan A. Leon received a grant of 85,067 shares of common stock. The shares are restricted stock that vest one-third per year over three years, meaning they become fully owned gradually over time. After this award, he directly holds 303,589 common shares. This is a compensation-related equity grant at no cash cost and does not involve any open-market buying or selling.